About Us
VK PREMIUM Business Consultants is a boutique consulting firm offering expert services to companies that aim to invest in the medical cannabis cultivation and processing field.
VK PREMIUM Medical Cannabis, a division of VK PREMIUM BUSINESS CONSULTANTS, always aims at the successful and profitable completion of your project. Through our vast network, deep experience and up-to-date know how, we facilitate the timely, successful implementation of your Medicinal Cannabis project. What sets our firm apart from among the top consultancy agencies in Greece are our consistency and quality services.
Which is our strongest competitive advantage?
Our strongest competitive advantage is our knowledge and experience regarding the Greek legislation and the necessary steps / actions required to accelerate the licensing and deployment of our clients' investments.
Starting with in depth analysis of the regulatory framework and legislation on the cultivation of medical cannabis, we aim to inform our clients about the legal conditions in Greece. Together we define and develop your strategy through a step by step process, defining all the stages that will lead to the achievement of your goal.
We help our clients grow their medical cannabis business providing guidance throughout all investment phases.
Successful completion of our clients’ projects is our top priority.
Feel free to contact
Call us at : +30 2106835560
Send email to : info@vkmedicalcannabis.com
Our Medicinal Cannabis Services
Strategic Planning
Investments - Funding
Land Identification
Blog
June 8, 2021
With the proposed law amendment the potential obstacles are removed to facilitate exports and the smooth production and distribution of finished cannabis products is guaranteed.
May 11, 2021
Up to 55% is the aid rate for the investments in vertical facilities for the cultivation and processing of medical cannabis in Greece. Maximum amount of aid: € 10,000,000.
May 10, 2021
The GKV have released data showing that the market for medical cannabis in Germany continued to grow in 2020, increasing by 34% compared to 2019 (excluding the newly added product Epidiolex)